Alfa Wassermann buys licence
Enlarge image


Alfa Wassermann buys licence

05.10.2012 - Italian Alfa Wassermann has acquired an exclusive licence for Theravance’s serotonin 5-HT4 agonist velusetrag.

The US biotech partner can bag up to US$63.5 plus royalties for the exclusive development and commercialisation rights of the treatment for gastrointestinal motility disorders such as constipation, irritable bowel syndrome, functional dyspepsia, and gastroparesis. The Bologna-headquartered pharma firm Alfa Wassermann, will fund Phase II clinical trials and grant Theravance a US$10m option fee payable if Alfa Wassermann exercises its option for Europe, Russia, China,  and other key markets after clinical proof-of-concept. The San Francisco-based biotech firm also is set to receive development, regulatory and sales milestone payments of up to US$53.5m. Additionally it may earn royalties on net sales of velusetrag (TD-5108) up to 20%.

What makes velusetrag so attractive to the Italians is its, up-to-now, beneficial safety profile. Previous treatments for gastrointestinal (GI) dysmotility targeting the 5-hydroxytryptamine(4) receptor, modified the function of the cardiac HERG potassium channel leading to severe adverse effects. Within the Phase II programme, the Italian firm will evaluate the efficacy, safety and tolerability of once-daily oral velusetrag in the treatment of patients with gastroparesis. The disorder has few therapeutic options and it is characterised by delayed gastric emptying in the absence of a mechanical obstruction with symptoms that include early satiety, nausea, vomiting and bloating. Velusetrag has been shown to accelerate gastric emptying in healthy volunteers.

Theravance will retain the full rights to the drug in the US, Canada, Japan and certain other countries. The US firm has completed a 400-patient Phase II proof-of-concept study in chronic idiopathic constipation for the drug. In the trial the compound demonstrated statistically significant prokinetic activity at all three doses (15 mg, 30 mg, and 50 mg) tested.

It was generally well tolerated and showed a low incidence of adverse events at the two lowest doses.



26.11.2015 Bioeconomy movers and shakers from every corner of the globe met this week at the world’s first Global Bioeconomy Summit in Berlin to discuss, debate and define better ways to ensure the bioeconomy succeeds on an international level.


24.11.2015 After weeks of speculation it is official: US pharma major Pfizer and Irish Botox maker Allergan will merge. With the deal, Pfizer is planning to dodge the high US taxes, causing indignation among US politicians.


23.11.2015 Amidst talk of the IPO window closing and cancelled flotations, diagnostics firms are still striking a chord with investors. Swedish Immunovia and German Curetis are successfully raising public money.


20.11.2015 French Sanofi and British AstraZeneca are giving open innovation a go: The two pharma giants will exchange thousands of compounds – for free.


19.11.2015 French gene editing company Cellectis has granted Servier the rights to bring cancer immunotherapy UCART19 to market. Servier in turn has teamed up with Pfizer to hurry development along.


17.11.2015 The first Italian accelerator specifically for biotech projects has been launched with help from Sofinnova Partners. The plan of BiovelocITA: to help Italy grow into one of Europe’s strongest biotech markets.


13.11.2015 Scientists in Bath, UK, have developed a medical dressing that turns fluorescent green when it detects infection. The researchers hope that the smart burns dressing will help fight antibiotic resistance.


13.11.2015 Out with the old: Roche is discarding four sites with 1,200 staff in an effort to restructure its manufacturing network for small molecules. Instead, a new manufacturing site will be built in Switzerland.


10.11.2015 Algae have many skills, but cancer fighting was not one of them – until now. Researchers from Australia and Germany have genetically engineered diatom algae to accurately deliver chemotherapeutic drugs.


10.11.2015 AstraZeneca has plucked Californian biopharma company ZS Pharma from under Actelion’s nose. The UK company is paying US$2.7bn (€2.5bn) to acquire ZS and its promising hyperkalaemia treatment currently under US regulatory review.


All Events


Strasbourg (F)

BioFIT 2015

Current issue

All issues

Product of the week


Stock list

All quotes


  • EVOCUTIS (UK)0.12 GBP33.33%
  • EPIGENOMICS (D)2.65 EUR17.26%


  • THERAMETRICS (CH)0.04 CHF-20.00%
  • SERODUS (N)2.18 NOK-18.35%
  • DEINOVE (F)5.14 EUR-17.63%


  • PLETHORA (UK)5.50 GBP91.0%
  • PROTHENA PLC (IE)75.31 USD46.2%


  • EPIGENOMICS (D)2.65 EUR-44.0%
  • RENEURON (UK)2.88 GBP-25.8%


  • KARO BIO (S)37.90 SEK5314.3%
  • CHRONTECH PHARMA (S)0.34 SEK1600.0%
  • GALAPAGOS (B)46.60 EUR260.1%


  • BIOTEST (D)15.31 EUR-81.0%
  • NEOVACS (F)0.80 EUR-76.5%

No liability assumed, Date: 29.11.2015